Targeting Kidney Cancer With Resirt, Preliminary Results Promising; Maintaining FVE for Sirtex
Promising initial safety and efficacy results from a pilot study of no-moat Sirtex's selective internal radiation therapy, or SIRT, using SIR-Spheres in patients with primary renal cell carcinoma, was presented at a meeting of the European Society for Medical Oncology. The conference presentation was the first public disclosure of data from Resirt, a pilot dose-escalating clinical study designed to assess safety and toxicity at 30 days after SIRT, in 21 patients not eligible for treatment by sur...Sirtex Medical is a global life-sciences company based in Australia. Co. is engaged in developing and delivering effective oncology treatments using novel small particle technology. Co.'s main product is a targeted radioactive treatment for liver cancer called SIR-Spheres® Y-90 resin microspheres. SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology and delivered to the liver via Selective Internal Radiation Therapy.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.